Papadopoulos Konstantinos, Iakovou Ioannis, Mantalovas Stylianos, Kosmidis Christoforos S, Laskou Stiliani, Karakousis Vasileios Alexandros, Sevva Christina, Dagher Marios, Roulia Panagiota, Kountouri Ismini, Kesisoglou Isaak, Sapalidis Konstantinos
3rd Surgical Department, University General Hospital of Thessaloniki "AHEPA", School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 1st St. Kiriakidi Street, 54621 Thessaloniki, Greece.
2nd Academic Nuclear Medicine Department, Academic General Hospital of Thessaloniki "AHEPA", Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Cancers (Basel). 2024 Dec 19;16(24):4236. doi: 10.3390/cancers16244236.
BACKGROUND/OBJECTIVES: Medullary thyroid carcinoma (MTC) is a highly aggressive tumor, as it is characterized by a high probability of local recurrence and distant metastases, even after surgical treatment. Early detection of disease recurrence is critical for improving long-term treatment outcomes and overall patient survival. By comparing different radiopharmaceuticals, this analysis aimed to strengthen existing guidelines and help bridge the gap between the recommendations of the ESMO and the ATA, highlighting the importance of PET/CT scanning in the postoperative follow-up of patients with MTC.
This research was carried out using three searchable databases, PubMed, ScienceDirect, and ResearchGate, resulting in 575 bibliographic studies up to the date of 20 June 2024. A meta-analysis of diagnostic accuracy was performed using the software Meta-DiSc, Version: 2.0 (Universidad Complutense, Barcelona, Spain), which led to aggregate assessments and the design of the SROC.
A quality assessment of the eligible studies was conducted, and the key findings were summarized.
Regardless of methodology, PET/CT scanning exhibits high sensitivity and specificity values in the diagnosis of local recurrence and metastases in surgical patients with medullary thyroid carcinoma. Furthermore, based on a comparative analysis of18F-FDG and GA68-DOTATE, it appears that these misunderstood radiopharmaceuticals are particularly sensitive and reliable for highlighting MTC, and it was found that there were no statistical differences in terms of sensitivity and specificity. Therefore, these two modalities appear to be complementary in monitoring MTC patients.
背景/目的:甲状腺髓样癌(MTC)是一种侵袭性很强的肿瘤,其特点是即使经过手术治疗,局部复发和远处转移的可能性也很高。疾病复发的早期检测对于改善长期治疗效果和患者总体生存率至关重要。通过比较不同的放射性药物,本分析旨在强化现有指南,并帮助弥合欧洲肿瘤内科学会(ESMO)和美国甲状腺协会(ATA)建议之间的差距,突出正电子发射断层扫描/计算机断层扫描(PET/CT)在MTC患者术后随访中的重要性。
本研究使用了三个可搜索的数据库,即PubMed、ScienceDirect和ResearchGate,截至2024年6月20日共检索到575项文献研究。使用Meta-DiSc软件2.0版(西班牙巴塞罗那康普顿斯大学)对诊断准确性进行荟萃分析,从而得出综合评估结果并设计汇总排序检验(SROC)。
对符合条件的研究进行了质量评估,并总结了主要发现。
无论采用何种方法,PET/CT扫描在诊断甲状腺髓样癌手术患者的局部复发和转移方面均表现出较高的敏感性和特异性值。此外,基于对18F-氟脱氧葡萄糖(18F-FDG)和镓68-奥曲肽(GA68-DOTATE)的比较分析,这些常被误解的放射性药物在突出显示MTC方面似乎特别敏感且可靠,并且发现它们在敏感性和特异性方面没有统计学差异。因此,这两种方法在监测MTC患者方面似乎具有互补性。